Robert M. Brody

Assistant Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Robert M. Brody is an Assistant Professor in the Department of Otorhinolaryngology – Head & Neck Surgery at the University of Pennsylvania in Philadelphia, USA. His research areas include the treatment outcomes of HPV-positive oropharyngeal carcinoma, trends in laryngeal squamous cell carcinoma incidence, and nutritional risks in postoperative settings for head and neck cancer patients. He has published notable articles on topics such as thyroid malignancies, adjuvant therapy choices, and risk factors in surgical reconstruction.

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Importance Laryngeal cancer has undergone a complex evolution in incidence, management, and standards of care over the past 20 years. Disease‐wide demographic and survival risk factors have yet to be elucidated. Objective Examine incidence, management, and survival trends in laryngeal cancer from 2000 to 2019. Design, Setting, and Participants The Surveillance, Epidemiology, and End Results database was utilized to identify age‐adjusted incidence rates (AAIRs) of laryngeal squamous cell carcinoma (LSCCa) from 2000 to 2019. Joinpoint regression was conducted to identify annual percentage changes (APCs). Chi‐squared analysis was used to find changes in demographic, clinicopathologic, and treatment changes over the study period. Finally, univariate Kaplan–Meier and COX multivariate regressions were conducted to identify survival differences. Results There were 46 266 cases of LSCCa identified between 2000 and 2019 with AAIR of 2.7 per 100 000 person‐years with APC of −2.6% [95% CI: −2.8% to 2.4%]. These rates have largely been down‐trending among demographic substratifications. Age at initial diagnosis has been increasing (64.6 → 66.0, p $75 000 2.2) and increased annual percentage decrease ( $75 000, −3.2%*). There were no other clinically significant differences in demographic and clinicopathologic trends although persistent demographic differences were noted. Late T‐stage at diagnosis has increased over the study period (T3, 18% → 23%, p < 0.001). Treatment with primary chemoradiotherapy has increased significantly (20.0% → 27.0%, p < 0.001). On univariate analysis, there were no significant differences in survival; however, on multivariate analysis, there has been a progressive improvement in disease‐specific and overall survival over 5‐year bins. Late‐stage disease had a progressive improvement in survival with each treatment period on both univariate and multivariate analysis. Conclusions and Relevance There has been a progressively significant decrease in age‐adjusted incidence of LSCCa with increased utilization of primary chemoradiotherapy. When adjusted for associated characteristics, there has been a continuing improvement in survival over the study period, primarily in late‐stage disease.

Year:

2025

Objectives Treatment of patients with head and neck squamous cell carcinoma of unknown primary (CUP) is challenging. Given the relative rarity of this condition and the recent use of primary transoral robotic surgery (TORS) in modern diagnostic and treatment algorithms, long‐term oncologic outcomes are unclear. The objectives were to evaluate oncologic outcomes of patients treated with TORS for management of CUP. Methods This retrospective case series was conducted at a tertiary care academic medical center from 2010 to 2021. All patients with HPV‐mediated CUP who underwent TORS‐assisted endoscopy were included. CUP was defined as biopsy‐proven squamous cell carcinoma in a cervical lymph node with uncertain primary location following standard‐of‐care clinical and radiologic assessment. Primary outcomes were recurrence‐free survival and overall survival. Secondary outcomes included usage of radiation and chemotherapy. Results In total, 157 patients were included in the study. Median follow‐up time was 62 months. Primary tumor was identified in 88% of patients. Surgery alone was performed in 21%, although adjuvant therapy was recommended but declined in 13%. Adjuvant radiation was completed in 46% and adjuvant chemoradiation in 33%. Two‐thirds of patients avoided chemoradiation. Overall survival was 94% and recurrence‐free survival was 92% at 5 years. Conclusion In the largest reported experience to date of TORS‐assisted management of CUP, we demonstrate that this approach facilitates a high rate of identification of occult mucosal malignancies and can eliminate the need for chemotherapy and potentially radiation therapy in select patients without compromising excellent oncologic and functional outcomes. Level of Evidence: 4.

Year:

2025

Background The geriatric nutritional risk index (GNRI) is a tool to assess preoperative nutritional status that can be calculated simply based on height, weight, and serum albumin. This study assesses the utility of GNRI in predicting postoperative complications in patients undergoing major head and neck cancer (HNC) surgery. Methods Retrospective review of the 2016–2020 National Surgical Quality Improvement Program database. Patients were categorized into GNRI > 98 (normal nutritional status), GNRI 92–98 (moderate malnutrition status), and GNRI < 92 (severe malnutrition status). Univariable and multivariable binary logistic regression analyses were performed. Results Sixteen thousand seven hundred eight‐nine patients undergoing HNC resection were included. On multivariable analysis, moderate and severe malnourishment based on GNRI remained significantly associated with any surgical complication, any medical complication, any complication, Clavien‐Dindo grade IV complications, and 30‐day mortality. Conclusions GNRI may have utility as a potentially modifiable preoperative prognostic factor that can be optimized to improve complications and mortality following HNC resection. Level of Evidence Level 4.

Year:

2025

Background Spindle epithelial tumors with thymus‐like differentiation (SETTLE) and carcinomas showing thymus‐like differentiation (CASTLE) are rare intrathyroid tumors. Methods This retrospective cohort study included patients diagnosed with SETTLE, CASTLE, and papillary thyroid carcinoma (PTC) from 2004 to 2020 within the National Cancer Database (NCDB). Demographic, tumor, and treatment characteristics were compared. Overall survival (OS) was analyzed using the Kaplan–Meier method and Cox regression models. Results This study identified 19 patients with CASTLE, 11 with SETTLE, and 483 474 with PTC. CASTLE and SETTLE patients had larger tumors, lymphovascular invasion, and positive surgical margins. They were rarely treated with radioactive iodine treatment but frequently received external beam radiation and chemotherapy. Five‐year OS was significantly lower for CASTLE and SETTLE compared to PTC. SETTLE was associated with an increased risk of death. Conclusion SETTLE and CASTLE are rare intrathyroid tumors with worse survival compared to PTC, often managed with radiation, chemotherapy, and surgery.

Year:

2025

Objective Undergoing surgery and adjuvant radiotherapy (aRT) at the same facility has been associated with higher overall survival (OS) in head and neck squamous cell carcinoma. Our study investigates whether undergoing surgery and aRT at the same academic facility is associated with higher OS compared with separate facilities in sinonasal squamous cell carcinoma (SNSCC). Methods The 2006 to 2017 National Cancer Database was queried for patients with SNSCC undergoing surgery at an academic facility followed by aRT with or without adjuvant chemotherapy. Multivariable binary logistic and Cox proportional hazards regression models were implemented. Results Of 419 patients satisfying inclusion criteria, 299 (71.4%) underwent surgery and aRT at the same academic facility. Residence in a less populated area (adjusted odds ratio [aOR] 1.75, 95% confidence interval [CI] 1.02–2.99, p = 0.042) and surgical facility case volume (aOR 2.51, 95% CI 1.21–5.21, p = 0.014) were associated with undergoing surgery and aRT at different facilities on multivariable logistic regression adjusting for patient demographics, clinicopathologic features, and adjuvant therapy ( p < 0.05). Five‐year OS was higher among patients undergoing surgery and aRT at the same academic facility (64% vs. 55%, p = 0.039). Undergoing surgery and aRT at different facilities remained associated with worse OS on multivariable Cox regression (aHR 1.90, 95% CI 1.09–3.32, p = 0.023). Conclusion Undergoing surgery and aRT at the same academic facility is associated with higher OS in SNSCC. Academic physicians should carefully consider the recommendation of aRT treatment facility based on the level of benefit that the patient may derive from coordinated multidisciplinary care. Level of Evidence 3 Laryngoscope , 135:705–715, 2025

Year:

2025

Objective Hypoalbuminemia (HA) is a proxy for malnutrition that has been associated with postoperative complications in several surgical subspecialties. This study investigates the association between pre‐operative HA and complications following major salivary gland (MSG) resection. Methods Patients undergoing outpatient, elective MSG resection were extracted from the 2005 to 2020 National Surgical Quality Improvement Program database. Demographics and comorbidities were compared between HA (preoperative serum albumin < 3.5 g/dL) and non‐HA cohorts. To determine associations between albumin status and postoperative complications, univariate and multivariable binary logistic regression analyses were performed. Results A total of 5774 patients undergoing MSG resection were included, of which 321 (5.6%) had preoperative HA. HA was associated with older age on univariate analysis (65.2 vs. 60.2 years, p < 0.001). Multivariable analysis found HA to be independently associated with any surgical complication (OR 2.03, 95% CI 1.09–3.56, p = 0.019) and length of stay (LOS) ≥ 90th percentile (OR 1.58, 95% CI 1.04–2.38, p = 0.032). Conclusion Preoperative HA may be a poor prognostic factor associated with an increased risk of surgical complications and prolonged LOS among patients undergoing MSG resection. Level of Evidence 4.

Year:

2025

Objective Investigate missed adjuvant therapy and associated disparities in overall survival (OS) for human papillomavirus‐associated (HPV+) oropharyngeal squamous cell carcinoma (OPSCC). Methods The 2010–2017 National Cancer Database was queried for patients with surgically resected HPV+ OPSCC. Indications for adjuvant radiotherapy (aRT) included pT3‐4 classification, pN2‐3 classification, lymphovascular invasion, pathologic extranodal extension (pENE), and/or positive surgical margins (PSM). Indication(s) for adjuvant chemoradiotherapy (aCRT) included pENE and/or PSM. Multivariable logistic and Cox regression models were implemented. Results Of 5297 patients satisfying inclusion criteria, 4288 had indication(s) for aRT; 775 did not receive any adjuvant therapy and were considered as missing aRT. A total of 2234 patients had indication(s) for aCRT. Of these, 1383 (61.9%) received aCRT, 555 (24.8%) patients received aRT alone and were considered as having missed aCRT, and 296 (13.2%) did not receive any adjuvant therapy. Missed aRT and missed aCRT were each associated with age, treatment facility type, pN classification, and surgical margin status ( p < 0.015). Among patients with indication(s) for aRT alone, OS of those receiving no adjuvant therapy, aRT alone, and aCRT was 90.0%, 94.8%, and 93.4%, respectively ( p = 0.080). Among patients with indication(s) for aCRT, those receiving aRT alone and aCRT had similar OS (89.0% vs. 86.6%, p = 0.357) which was superior to receiving no adjuvant therapy (74.9%, p < 0.001). These patterns in OS persisted on multivariable Cox regression. Conclusion Among patients with HPV+ OPSCC and indication(s) for aRT, missed aRT was not associated with worse OS. For patients with indication(s) for aCRT, aRT alone was associated with similar OS as aCRT. Level of Evidence 3 Laryngoscope , 135:729–740, 2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Sambit Kumar Mishra

Bioinformatics Scientist

Division of Cancer Epidemiology and Genetics, National Cancer Institute

UNITED STATES
View details

Alexander Lin

Morton M. Kligerman, MD Endowed Professor

University of Pennsylvania

UNITED STATES
View details

Timothy Chao

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Praneet Kaki

Thomas Jefferson University

UNITED STATES
View details